Effects of the microbial secondary metabolites pyrrolnitrin, phenazine and patulin on INS-1 rat pancreatic β-cells
Abstract The effects on pancreatic β-cell viability and function of three microbial secondary metabolites pyrrolnitrin, phenazine and patulin were investigated, using the rat clonal pancreatic β-cell line, INS-1. Cells were exposed to 10-fold serial dilutions (range 0–10 µg mL−1) of the purified com...
Saved in:
Published in | FEMS immunology and medical microbiology Vol. 63; no. 2; pp. 217 - 227 |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | English |
Published |
Oxford, UK
Blackwell Publishing Ltd
01.11.2011
Blackwell Oxford University Press |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Abstract
The effects on pancreatic β-cell viability and function of three microbial secondary metabolites pyrrolnitrin, phenazine and patulin were investigated, using the rat clonal pancreatic β-cell line, INS-1. Cells were exposed to 10-fold serial dilutions (range 0–10 µg mL−1) of the purified compounds for 2, 24 and 72 h. After 2 h exposure, only patulin (10 µg mL−1) was cytotoxic. All compounds showed significant cytotoxicity after 24 h. None of the compounds altered insulin secretion with 2 and 20 mM glucose after 2 h. However, after 24 h treatment, phenazine and pyrrolnitrin (10 and 100 ng mL−1) potentiated insulin production and glucose-stimulated insulin secretion, whereas patulin had no effect. Exposure (24 h) to either phenazine (100 ng mL−1) or pyrrolnitrin (10 ng mL−1) caused similar increases in the Ca2+ content of INS-1 cells. The outward membrane current was inhibited after 24 h exposure to either phenazine (100 ng mL−1) or pyrrolnitrin (10 or 100 ng mL−1). This study presents novel data suggesting that high concentrations of pyrrolnitrin and phenazine are cytotoxic to pancreatic β-cells and thus possibly diabetogenic, whereas at lower concentrations these agents are nontoxic and may be insulinotropic. The possible role of such agents in the development of cystic fibrosis-related diabetes is discussed. |
---|---|
ISSN: | 0928-8244 1574-695X 2049-632X |
DOI: | 10.1111/j.1574-695X.2011.00844.x |